Our Investors
Puerto Rico Science Trust
Investors
Investors
Investors
Investors
Investors
Our Practice
​
The company works on finding cures for the diseases such as: Tuberculosis and leprosy. we begin by manufacture products from natural herbs. In addition, we work with plants that we can find in the flora of Puerto Rico, to promote our country's products.
​
Forthermore, our purpose is based on becoming the best worldwide company on helping people fight the leprosy and Tuberculosis. Also we want to develop other benefits for the patients so that they can see how much the trietment actually works, not only by inhibiting the disease but also by making their antibodies more strong against other diseasses.
THE PRACTICE
Latest Company News:
Grand Opening
June 24, 2016
​
IDMA Puerto Rico has formaly been stablish as a company at June 26, 2016. It's purpose is to help people with Tubercolosis and Leprosy. This company started as an idea to revolutionize the farmacologic industry.
​
The creator and CEO of the company Is Armando J. Mujica, a young man of only 17 years old. He started this company because he wanted to end with the world re-emergent diseases such as: Tuberculosis and Leprosy. That's how then he started selling his idea untill now.
​
​
Reasherch State
Jun 25, 2016
​
The company still in reasherch to start developing the new generation of plants that can inhibit the Mycobacterium bacterias. The plants that are being used are Puerto Rican plants, because it's a way of promoting the Puerto Rican flora and of developing Puerto Rico in the discovery of plants that can be use as antibiotics.
​
IDMA Corp. gives explain their proposal
Jun 25, 2016
IDMA Corp. present their ideas and purposes on June 25, 2016 to get investors to promote the proposal. They express how would the company work and to what public they would be impacting. Based on what it was said the IDMA principal consumer are the pharmacies and the product is directed to those people that are suffering of Tuberculosis or Leprosy.
​
The Idea of IDMA Corp. it's to stablish a product that is cost effective to those people that can afford a drug for Leprosy or Tuberculosis but that is as effective as the other products in the pharmaceutical market.